Prevalence of MACE and CV manifestations according to the main features leading to RTHβ diagnosis.
| Features leading to RTHβ diagnosis . | N (%) . | CV manifestations at diagnosis N . | MACE events at diagnosis N . |
|---|---|---|---|
| Familial screening | 136 (47.9%) | 28 | 8 |
| Failure to thrive/ADHD | 27 (9.5%) | 2 | 0 |
| Incidental finding | 18 (6.3%) | 0 | 0 |
| Nodular goiter | 15 (5.3%) | 2 | 0 |
| Hypothyroidism refractory to treatment | 7 (2.5%) | 2 | 1 |
| Graves’ diseasea | 2 (0.7%) | 0 | 0 |
| Thyrotoxic features (tachycardia N = 37 or other features N = 33) | 70 (24.6%) | 50 | 6 |
| Cardiac arrhythmias N = 8 (atrial fibrillation, paroxysmal supraventricular tachycardia) or heart failure N = 1 | 9 (3.2%) | 9 | 9 |
| Total | 284 | 93 | 24 |
| Features leading to RTHβ diagnosis . | N (%) . | CV manifestations at diagnosis N . | MACE events at diagnosis N . |
|---|---|---|---|
| Familial screening | 136 (47.9%) | 28 | 8 |
| Failure to thrive/ADHD | 27 (9.5%) | 2 | 0 |
| Incidental finding | 18 (6.3%) | 0 | 0 |
| Nodular goiter | 15 (5.3%) | 2 | 0 |
| Hypothyroidism refractory to treatment | 7 (2.5%) | 2 | 1 |
| Graves’ diseasea | 2 (0.7%) | 0 | 0 |
| Thyrotoxic features (tachycardia N = 37 or other features N = 33) | 70 (24.6%) | 50 | 6 |
| Cardiac arrhythmias N = 8 (atrial fibrillation, paroxysmal supraventricular tachycardia) or heart failure N = 1 | 9 (3.2%) | 9 | 9 |
| Total | 284 | 93 | 24 |
aGraves’ disease patients had suppressed TSH at diagnosis and central hyperthyroidism become evident following thionamides treatment.
CV cardiovascular, ADHD attention deficit hyperactivity disorder.
Prevalence of MACE and CV manifestations according to the main features leading to RTHβ diagnosis.
| Features leading to RTHβ diagnosis . | N (%) . | CV manifestations at diagnosis N . | MACE events at diagnosis N . |
|---|---|---|---|
| Familial screening | 136 (47.9%) | 28 | 8 |
| Failure to thrive/ADHD | 27 (9.5%) | 2 | 0 |
| Incidental finding | 18 (6.3%) | 0 | 0 |
| Nodular goiter | 15 (5.3%) | 2 | 0 |
| Hypothyroidism refractory to treatment | 7 (2.5%) | 2 | 1 |
| Graves’ diseasea | 2 (0.7%) | 0 | 0 |
| Thyrotoxic features (tachycardia N = 37 or other features N = 33) | 70 (24.6%) | 50 | 6 |
| Cardiac arrhythmias N = 8 (atrial fibrillation, paroxysmal supraventricular tachycardia) or heart failure N = 1 | 9 (3.2%) | 9 | 9 |
| Total | 284 | 93 | 24 |
| Features leading to RTHβ diagnosis . | N (%) . | CV manifestations at diagnosis N . | MACE events at diagnosis N . |
|---|---|---|---|
| Familial screening | 136 (47.9%) | 28 | 8 |
| Failure to thrive/ADHD | 27 (9.5%) | 2 | 0 |
| Incidental finding | 18 (6.3%) | 0 | 0 |
| Nodular goiter | 15 (5.3%) | 2 | 0 |
| Hypothyroidism refractory to treatment | 7 (2.5%) | 2 | 1 |
| Graves’ diseasea | 2 (0.7%) | 0 | 0 |
| Thyrotoxic features (tachycardia N = 37 or other features N = 33) | 70 (24.6%) | 50 | 6 |
| Cardiac arrhythmias N = 8 (atrial fibrillation, paroxysmal supraventricular tachycardia) or heart failure N = 1 | 9 (3.2%) | 9 | 9 |
| Total | 284 | 93 | 24 |
aGraves’ disease patients had suppressed TSH at diagnosis and central hyperthyroidism become evident following thionamides treatment.
CV cardiovascular, ADHD attention deficit hyperactivity disorder.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
